tbuckley/cabot-search huggingface dataset:
Reply:
Authors: Anna Mae Diehl
Journal: Hepatology (2012)

Reply: Balsano et al. studied Huh7.5 cells to evaluate the effects of Hedgehog (Hh) signaling on lipotoxicity. They concluded that Hh pathway inhibitors might be harmful in nonalcoholic fatty liver disease (NAFLD) because inhibiting Hh signaling in the malignant hepatocytes increased lipid accumulation. It is difficult to apply findings in cultured cancer cells to advance understanding of metabolism in nonmalignant hepatocytes because metabolism is fundamentally different in malignant and nonmalignant cells. Compared to benign hepatocytes, for example, malignant hepatocytes rely much more heavily on glycolysis (the Warburg effect).1 More important, nonmalignant hepatocytes are not Hh-responsive. Thus, hepatocytes in NAFLD livers would not be expected to respond directly to treatment with an Hh inhibitor. Rather, mature hepatocytes produce Hh ligands when injured. These hepatocyte-derived Hh ligands, in turn, initiate Hh signaling in neighboring stromal and progenitor cells. It is the Hh signaling in those nonhepatocyte cell types that drives hepatic fibrogenesis, recruitment of inflammatory cells, vascular remodeling, and progenitor accumulation.2 Thus, the desired "targets" for Hh inhibitors in NAFLD are nonparenchymal cells that participate in fibrogenic repair, not the hepatocytes per se. Finally, because Hh signaling inhibits lipogenesis in Hh-responsive cells,3 it is predictable that inhibiting Hh signaling would increase lipid accumulation in Huh7.5 cells. Triglyceride synthesis actually protects hepatocytes from toxic fatty acids.4 Thus, although not directly examined, Hh pathway inhibition might have improved Huh7.5 cell viability by enhancing lipogenesis. We hope that our response is helpful to the authors and thank them for their interest in our work.
Vaccination Coverage of 2-Year-Old Children—United States, 1992-1993
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fibrinolysin
Authors: Virgil A. Place
Journal: JAMA (1961)

<h3>To the Editor:—</h3> In the issue ofThe Journalfor Jan. 28, 1961, in which the major emphasis was on the use of fibrinolytic therapy, I was amazed at your inclusion of the paper, "Acute Coronary Thrombus and Fibrinolysin" (H. E. Bolton, et al.,<i>JAMA</i><b>175:</b>307). Regardless of their conclusions about the dramatic results, it seems that you have some responsibility as an editor. My initial impression when I read the title was that I was going to find out about results in human beings. Instead, I find that this is a single case report on a 12-kg. mongrel. It would have been no great strain for these authors to have found 5 more 12-kg. dogs—or any other number—because the type of experiment that was performed was not exceedingly difficult, and it could have been repeated daily at least for several weeks to add some significance to the report.
La hipertension arterial, hipertonia arterial o hiperpiesis y los estados hipertensivos, hipertónicos o de hiperpiesia.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase changes in membrane lipids in sickle red cell shed‐vesicles and sickle red cells
Authors: Maxwell P. Westerman, Lillie Unger, Omer Kucuk, Peter Quinn, Leonard J. Lis
Journal: American Journal of Hematology (1998)

Lipid phase transformations may occur in the membranes of sickle red cell shed-vesicles and sickle red cells. The presence of such phase changes could be important in sickle cell disease since membrane phase changes appear to contribute to the generation of antiphospholipid antibodies that are thrombophilic and occur in sickle cell disease. In the present study, we have evaluated sickle red cell shed-vesicles and sickle red cells for the presence of non-bilayer lipid phases using 31P-NMR spectroscopy. Results show that the spectra of both the shed-vesicles and the sickle red cells are compatible with the occurrence of non-bilayer phases in the membrane bilayers. The findings support the concept that these membranes could contribute to the generation of antiphospholipid antibodies in sickle cell disease. Am. J. Hematol. 58:177–182, 1998. © 1998 Wiley-Liss, Inc.
Two Cases of Hantavirus Pulmonary Syndrome—Randolph County, West Virginia, July 2004
Journal: JAMA (2005)

HANTAVIRUS PULMONARY SYNDROME (HPS) is a rare cardiopulmonary disease caused by viruses of the genus Hantavirus, for which rodents are the natural reservoir. 1,2Transmission to humans occurs by direct contact with rodents or their excreta or by inhalation of aerosolized infectious material (e.g., dust created by disturbing rodent nests).In July 2004, HPS cases (including one fatal case) were reported in two persons believed to have been exposed at sites approximately 12 miles apart in Randolph County, West Virginia (2000 population: 28,254). 3 This report describes the two cases and summarizes their epidemiologic and environmental investigations.Clinicians and the public need to be educated about the risk for HPS and methods to reduce that risk. Case Investigations
Klinische Wochenschrift, Berlin
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table Errors
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA gets Goethe trophy for antismoking efforts
Authors: A. A. Skolnick
Journal: JAMA (1996)

WHILE the German writer Johann Wolfgang von Goethe (1749-1832) is renowned for his<i>Faust</i>and other literary works, few people know that he was an ardent crusader against active and passive smoking. The establishment of the Goethe Challenge Trophy, presented this year to the American Medical Association (AMA) for its leadership in the war against the tobacco pandemic, has focused attention on that obscure aspect of the poet-philosopher's multiple interests. At a ceremony in October at AMA headquarters in Chicago, Ill, Frank Montgomery, MD, vice president of the German Medical Association, presented the trophy—a 42-lb silver bust of Goethe—to the Association along with a framed citation. "This trophy was commissioned to be awarded annually to an institution that has excelled in promoting a smoke-free environment, especially among health care professionals, thus making an example for society at large," he said. The Goethe Challenge Trophy was established by Friedrich Portheine, MD,
Highlights
Journal: JAMA Oncology (2016)

This randomized clinical trial sought to determine whether neratinib plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel as fi rst-line therapy in recurrent and/or metastatic ERBB2-positive breast cancer.A total of 479 women received neratinib (240 mg/d orally) or trastuzumab (4 mg/kg then 2 mg/kg weekly), each combined with paclitaxel (80 mg/m 2 on days 1, 8, and 15 every 28 days).There was no statistically signifi cant diff erence in median progression-free survival.Awada and colleagues concluded that neratinib-paclitaxel is not superior to trastuzumab-paclitaxel in terms of progression-free survival for this population.Pegram provides an Editorial.
Truth Survival
Authors: William C. Holmes
Journal: Annals of Internal Medicine (2002)

Letters3 December 2002Truth SurvivalWilliam C. Holmes, MD, MSCEWilliam C. Holmes, MD, MSCEUniversity of Pennsylvania School of Medicine; Philadelphia, PA 19104-6021Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-11-200212030-00016-w1 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Poynard and colleagues (1) make an important contribution to the literature at a time when the dogma of medical practice has recently undergone major shifts in assumed truth (for example, recent findings in hormone replacement therapy). I applaud the authors for the question they posed, the extensive work they did, and their cogent presentation of a complex idea and analysis. Because of problems with their analysis, however, their suggestion of a requiem for evidence-based medicine is premature.Survival analysis is named for its most common use, which is analyzing the duration of survival until death. The question ...Reference1. Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J, et al . Truth survival in clinical research: an evidence-based requiem? Ann Intern Med. 2002;136:888-95. [PMID: 12069563] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: William C. Holmes, MD, MSCEAffiliations: University of Pennsylvania School of Medicine; Philadelphia, PA 19104-6021 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTruth Survival in Clinical Research: An Evidence-Based Requiem? Thierry Poynard , Mona Munteanu , Vlad Ratziu , Yves Benhamou , Vincent Di Martino , Julien Taieb , and Pierre Opolon Truth Survival Michael P. LaValley and David T. Felson Truth Survival Thierry Poynard , Mona Munteanu , and Vlad Ratziu Metrics 3 December 2002Volume 137, Issue 11Page: W1KeywordsEvidence based medicineHormone replacement therapySurvival analysis ePublished: 3 December 2002 Issue Published: 3 December 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Fetal Loss and Caffeine Intake
Authors: Jennie Kline
Journal: JAMA (1994)

<h3>To the Editor.</h3> —Infante-Rivard et al<sup>1</sup>conclude that caffeine intake during pregnancy causes spontaneous abortion. They cite our study of karyotyped losses, but disregard our interpretation.<sup>2</sup> About half of spontaneous abortions have chromosome aberrations. This diversity allows application of two criteria to assess causality: (1) an association specific to a particular type of loss and (2) the time of exposure coherent with pathogenesis.<sup>3</sup> Chromosomal aberrations arise no later than conception, and some long before; over 90% of conceptuses are nonviable and abort spontaneously. Exposure to caffeine after conception cannot cause aberrations, nor is it likely to produce detectable increases in loss rates because aberrations are already so highly lethal. By contrast, causes of chromosomally normal loss might operate either before or after conception; causal effects of exposure during pregnancy are biologically plausible. We studied 899 karyotyped cases and 1423 controls (deliveries, ≥28 weeks). We compared cases with
Abstract 3894: Copy number alterations in urothelial carcinomas: Their clinicopathological significance and correlation with DNA methylation alterations
Authors: Naotaka Nishiyama, Eri Arai, Ryo Nagashio, Hiroyuki Fujimoto, Fumie Hosoda, Tatsuhiro Shibata, Taiji Tsukamoto, Sana Yokoi, Issei Imoto, Johji Inazawa, Yae Kanai
Journal: Cancer Research (2011)

Abstract Purpose: The aim of this study was to clarify the genetic backgrounds underlying the clinicopathological characteristics of urothelial carcinomas (UCs). Experimental Design: We analyzed copy number alterations by array comparative genomic hybridization analysis using a high-resolution (244K) oligonucleotide array, DNA methylation alterations on a genome-wide scale using bacterial artificial chromosome array-based methylated CpG island amplification, and DNA methylation status on C-type CpG islands using bisulfite modification in 49 samples of UCs of the urinary bladder, ureter and renal pelvis. The clinicopathological significance of copy number alterations and the correlations between alterations of copy number and those of DNA methylation were examined. Results: Losses of 2q33.3-q37.3, 4p15.1-q26 and 5q13.3-q35.2 and gains of 7p11.2-q11.23 and 20q13.11-q13.31 were correlated with higher histological grade, and gain of 7p21.2-p21.1 was correlated with deeper invasion. Losses of 6q14.1-q27 and 17p13-q11.1 and gains of 19q13.11-q13.12 and 20q13.12-q13.33 were correlated with lymph vessel involvement. Loss of 16p12.2-p12.1 and gains of 3q26.31-q29 and 20q13.2-q13.33 were correlated with vascular involvement. Losses of 5q14.1-q23.2, 6q14.1-q27, 8p22-p21.3, 11q13.5-q14.1 and 15q11.2-q22.2 and gains of 3q27.3-q29, 7p11.2-q11.22, 10p13-p12.33, 12q24.31 and 19q13.11-q13.2 were correlated with the development of aggressive non-papillary UCs. Losses of 1p33-p31.1, 2q22.1-q23.1, 10q11.23-q21.1 and 15q21.3 were correlated with tumor recurrence. Unsupervised hierarchical clustering analysis based on copy number alterations clustered UCs into three subclasses, clusters A, B1 and B2: copy number alterations associated with genome-wide DNA hypomethylation, regional DNA hypermethylation on C-type CpG islands associated with chromosomal losses, and genome-wide DNA hypo- and hypermethylation, were accumulated in clusters A, B1 and B2, respectively. Conclusions: There is a need to explore tumor-related genes that may encode potential therapeutic targets at chromosomal loci where copy number alterations are correlated with clinicopathological parameters reflecting the malignant potential of UCs. Chromosomal loci where copy number alterations are correlated with UC recurrence may be potential indicators of prognosis. Both genetic and epigenetic events appear to accumulate during urothelial carcinogenesis, reflecting the clinicopathological diversity and histological heterogeneity of UCs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3894. doi:10.1158/1538-7445.AM2011-3894
Intravenous iron dextran in clinical medicine
Authors: R. D. Hamstra
Journal: JAMA (1980)

Four hundred seventy-one adult patients and ten adult prisoner volunteers received 2,099 intravenous (IV) injections of iron dextran (Imferon), usually 250 to 500 mg at less than 100 mg/min. Intravenous iron supplies enough iron to permit RBC formation greater than 50 mL/day and repletion of tissue iron. Tissue iron did not always supply iron at an optimal rate. Hemoglobin production was higher after IV than oral or intramuscular iron if the hemoglobin level was less than 9 g/dL. Three life-threatening immediate anaphylactoid and eight severe delayed reactions were observed. There were no deaths. Delayed reactions were more frequent in women and collagen-vascular diseases and less frequent in pregnancy. Because anaphylactoid reactions are serious and unpredictable, IV iron dextran should be used only when iron deficiency anemia cannot be treated adequately with oral iron. (<i>JAMA</i>243:1726-1731, 1980)
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
Authors: M. de Bruin-Weller, D. Thaçi, C.H. Smith, K. Reich, M.J. Cork, A. Radin, Q. Zhang, B. Akinlade, A. Gadkari, L. Eckert, T. Hultsch, Z. Chen, G. Pirozzi, N.M.H. Graham, B. Shumel
Journal: British Journal of Dermatology (2018)

Atopic dermatitis (also called AD or eczema) is a chronic skin disease found in up to 1 in 10 adults, causing itchy rashes that may cover most of the body. Ciclosporin, an oral treatment (taken by mouth) commonly used for AD, doesn't always work and can have significant side effects. Other broadly‐acting oral medications are sometimes used, but not approved, for AD. Dupilumab is a new medication approved in many countries for adults with inadequately controlled moderate‐to‐severe AD. Dupilumab specifically targets pathways in the body that drive AD. Researchers in Europe evaluated how well dupilumab injections improved rashes, itch, and daily lives of people whose AD required ciclosporin, but for whom ciclosporin wasn't working or caused intolerable side effects, or whose medical conditions prevented its use. Among 325 participants, 110 received 300 mg dupilumab once‐weekly, 107 received it every two weeks, and 108 received placebo (dummy drug) once‐weekly. All participants used topical (applied to the skin) corticosteroids during the 16‐week study. Dupilumab improved AD rashes: at Week 0, participants’ Eczema Area and Severity Index (EASI) scores were about 31 (scale: 0–72), but by Week 16, 59% to 62% of dupilumab‐treated participants achieved 75% or greater improvement in EASI, versus 29.6% of people on placebo. Dupilumab also improved itch, other symptoms, mood, and quality of life. Conjunctivitis and injection‐site reactions were more frequent among dupilumab‐treated patients; skin infections (excluding herpes) and AD exacerbations (worsening) were more frequent with placebo. The authors conclude that dupilumab plus topical corticosteroids significantly improved AD even in adults with AD who had previously failed treatment with or were unable to use ciclosporin.
Benefits and harms of conservative, pharmacological, and surgical management options for women with bladder outlet obstruction: A systematic review from the European Association of Urology non-neurogenic female LUTS guidelines panel
Authors: B. Peyronnet, M.I. Omar, E. O’Connor, L. Tzelves, A. Nic An Riogh, M. Manso, C. Yuan, S. Arlandis, K. Bo, E. Costantini, F. Farag, J. Groen, A. Nambiar, V. Phé, H. Van Der Vaart, J. N’Dow, C. Harding, M.C. Lapitan
Journal: European Urology (2021)
MODERN IDEAS CONCERNING PUERPERAL ECLAMPSIA.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal